THE AGGRESSIVENESS OF MURINE LYMPHOMAS SELECTED IN VIVO BY GROWTH RATE CORRELATES WITH GALECTIN-1 EXPRESSION AND RESPONSE TO CYCLOPHOSPHAMIDE

ZACARIAS FLUCK M; HESS L; SALATINO M; CROCI DO; STUPIRSKI JC; DI MASSO RJ; ROGGERO E; RABINOVICH GA; SCHAROVSKY OG* (GAR AND OGS COMPARTEN ÚLTIMA AUTORÍA)

CANCER IMMUNOLOGY IMMUNOTHERAPY

SPRINGER

Lugar: Berlin; Año: 2012 vol. 61 p. 469 - 480

0340-7004

Although lymphomas account for almost half of blood-derived cancers that are diagnosed each year, the causes of new cases are poorly understood, as reflected by the relatively few risk factors established. Galectin-1, an immunoregulatory ß-galactoside-binding protein, has been widely associated with tumor-immune escape. The aim of the present work was to study the relationship between tumor growth rate, aggressiveness, and response to cyclophosphamide (Cy) therapy with regard to Gal-1 expression in murine T-cell lymphoma models. By means of a disruptive selection process for tumor growth rate, we generated two lymphoma variants from a parental T-cell lymphoma, which have unique characteristics in terms of tumor growth rate, spontaneous regression, metastatic capacity, Gal-1 expression and sensitivity to Cy therapy. Here, we show that Gal-1 expression strongly correlates with tumor growth rate, metastatic capacity and response to single-dose Cy therapy in T-cell lymphoma models; this association might have important consequences for evaluating prognosis and treatments of this type of tumors.